Ocugen Inc (NASDAQ: OCGN) recently announced that the Independent Data and safety monitory Board evaluated the safety data recorded during the clinical trial of its drug OCU400. The compound was developed to treat Retinitis Pigmentosa, an eye disease where the retina is damaged, thus leading to vision impairment.
The board recommends that the company recruit patients
One of the recommendations issued by the board was that the company should begin the process of recruiting participants for the study.
Ocugen began the study to observe the efficiency of the compound as a modifier gene therapy candidate. The board suggested that the company recruit individuals for the remaining section of the study. During the announcement, the company’s Chief Officer, Mark Penessi, stated that the recommendation was the beginning of a step in the right direction.
The treatment didn’t have major side effects
Penessi further stated that the compound produced minor side effects; thus, the company was anticipating finding out how the compound affected the retinal deterioration and providing a permanent solution for patients affected.
The therapy takes out the receptors that regulate various roles of the retina, thus enabling it to attack any pathogens belonging to retina illnesses. OCU400 can be contrasted with the traditional forms of therapy as it only transforms a portion of the retina’s functions, thus enabling it to tackle one mutation or illness at a time.
Ocugen Inc is among the leading companies in the biopharmaceutical industry that focuses on identifying, creating, and marketing gene therapy that enhances the lives of individuals in the community. The company is making significant results by creating specific products and distributing efficient services to their consumers, patients and physicians.
Encompassed with a talented and award-winning team, the company is consistent and reliable to all parties connected to it. The gene modifier treatment possesses the capacity to treat more than one form of illness, thus providing chances for individuals with certain medical skills. Ocugen is available on platforms including LinkedIn and Twitter for any investor or third parties interested in the company. Ocugen is located in Great Valley, Pennsylvania, and has several subsidiaries and partners, including Bharat Biotech, CansinoBio, and others.
